Prescription Cholesterol Medications Guide

Why prescription cholesterol medications matter

Prescription cholesterol medications lower LDL cholesterol far more than lifestyle changes alone, and in clinical trials they reduce heart attacks, strokes, and cardiovascular death. In the CTT meta-analysis of 26 trials, every 39 mg/dL drop in LDL-C cut major cardiovascular events by about 22%.

Diet and exercise are important. They improve cholesterol, cardiovascular fitness, and blood pressure. But for many people, lifestyle changes alone don't reach the LDL levels linked to the lowest risk. This applies most to people with a genetic cause (like familial hypercholesterolemia or elevated Lp(a)), those with existing plaque, or those whose LDL-C and ApoB stay high despite a healthy lifestyle.

Statins

Statins are the most widely prescribed cholesterol medications and the first step for most people. They block an enzyme in the liver (HMG-CoA reductase) that makes cholesterol. The most common are atorvastatin (Lipitor), rosuvastatin (Crestor), simvastatin, and pravastatin, all available as low-cost generics.

How much they lower cholesterol: High-intensity statins lower LDL-C by about half. In atorvastatin's prescribing trials, 40 mg lowered LDL-C by 50% and 80 mg by 60% (Lipitor prescribing information).

What the evidence shows: The CTT meta-analysis, covering over 170,000 patients across 26 trials, found that each 1 mmol/L (about 39 mg/dL) reduction in LDL-C reduced major cardiovascular events by approximately 22%.

Side effects: Muscle aches are the most common complaint. When they happen, you have options: a lower dose, a different statin, or adding non-statin therapies. If statins haven't worked for you, see our approach to statin intolerance and our guide to statin side effects.

Ezetimibe

Ezetimibe (Zetia) is an inexpensive generic pill that blocks cholesterol absorption in the intestine. It's most often added to a statin for extra LDL lowering.

How much it lowers cholesterol: About 18% on its own. Added to an ongoing statin, it lowered LDL-C by a further 25%, compared with 4% for continuing the statin alone, per the Zetia prescribing information.

Why it helps: People tolerate it well, it costs little, and in IMPROVE-IT, adding it to a statin after a heart attack or unstable angina modestly lowered cardiovascular events.

Bempedoic acid

Bempedoic acid (Nexletol) is a daily non-statin pill that works one step upstream of statins in the cholesterol production pathway. It's especially useful for people with statin muscle side effects, because it's activated mainly in the liver rather than in muscle. It also comes combined with ezetimibe (Nexlizet).

How much it lowers cholesterol: About 18% more than placebo when added to a statin, in the CLEAR Harmony trial.

What the evidence shows: In CLEAR Outcomes, in about 14,000 people who couldn't take statins, bempedoic acid lowered major cardiovascular events by 13%. The 2026 ACC/AHA multisociety guideline elevated it to a first-line non-statin option (ACC).

PCSK9 inhibitors

PCSK9 inhibitors are the most powerful add-on cholesterol medicines, lowering LDL-C by roughly another 50 to 60% on top of a statin. They work by helping the liver remove more LDL particles from the blood, and they now come in several forms:

• Evolocumab (Repatha) and alirocumab (Praluent): injectable antibodies, self-injected every two to four weeks
• Enlicitide (Lipfendra): the first oral PCSK9 inhibitor, FDA-approved in July 2026 and taken as a daily pill (Lipfendra guide)
• Lerodalcibep (Lerochol): FDA-approved in December 2025 and launched in the US in May 2026, a self-injection given once a month (Lerochol guide)

See PCSK9 inhibitors explained for a deeper comparison, or how to get a PCSK9 inhibitor prescription.

How much they lower cholesterol: In FOURIER, adding evolocumab to a statin lowered LDL-C by 59% and reduced heart attacks, strokes, and related events by 15%.

What the evidence shows: The GLAGOV trial found that evolocumab also shrank plaque inside the coronary arteries, with regression in 64% of patients on evolocumab compared with 47% on placebo.

Inclisiran

Inclisiran (Leqvio) is an siRNA (small interfering RNA) shot that tells the liver to make less PCSK9. A healthcare professional gives it twice a year after the first two doses.

How much it lowers cholesterol: About 50% compared with placebo, in the ORION-10 and ORION-11 trials.

Why it stands out: Twice-yearly dosing replaces daily pills and frequent injections. Its outcomes trials haven't reported yet. More in our Leqvio guide.

Highly purified EPA (icosapent ethyl)

Icosapent ethyl (Vascepa) is a purified omega-3 fatty acid for people with high triglycerides despite a statin. In REDUCE-IT, 8,179 such patients had a 25% lower risk of major cardiovascular events with icosapent ethyl than with placebo, over a median of 4.9 years.

How do these medications work together?

Treatment is usually stepped: a statin first, then non-statin medicines added until LDL and ApoB reach goal. No single medication is right for everyone. A typical sequence:

1. Start with a statin at the highest dose you tolerate
2. If LDL stays above goal, add ezetimibe and/or a PCSK9 inhibitor; the 2026 ACC/AHA multisociety guideline says this escalation "should be implemented without delay" (ACC)
3. Consider bempedoic acid or inclisiran, especially if statins aren't tolerated
4. Add icosapent ethyl when triglycerides stay high

The same guideline sets an LDL-C goal under 70 mg/dL for people with cardiovascular disease and under 55 mg/dL for those at very high risk. Getting there takes follow-up, so Preval Health reassesses every 90 days with advanced lipid testing such as ApoB.

How do you get these medications?

If a statin alone hasn't reached your target, or hasn't worked at all, you can get these medications directly through our cash-pay pathway, without a prior authorization wait.